293 related articles for article (PubMed ID: 17213509)
1. 45 years later...where do we stand?
Benegbi M
Can J Clin Pharmacol; 2007; 14(1):e37-9. PubMed ID: 17213509
[No Abstract] [Full Text] [Related]
2. Challenges in drug use near term and during delivery.
Farine D
Can J Clin Pharmacol; 2007; 14(1):e29-33. PubMed ID: 17213507
[No Abstract] [Full Text] [Related]
3. Drugs in pregnancy.
Koren G; Pastuszak A; Ito S
N Engl J Med; 1998 Apr; 338(16):1128-37. PubMed ID: 9545362
[No Abstract] [Full Text] [Related]
4. Inactive pharmaceutical ingredients : implications for pregnancy.
Finkelstein Y; Rezvani M; Garcia-Bournissen F; Nurmohamed L; Koren G
Can J Clin Pharmacol; 2007; 14(1):e17-28. PubMed ID: 17213505
[No Abstract] [Full Text] [Related]
5. Collection and analysis of drug safety data in pregnancy.
Moretti M
Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
[No Abstract] [Full Text] [Related]
6. Drugs in pregnancy: acknowledging challenges--finding solutions.
Koren G; MacLeod S; Davis D
Can J Clin Pharmacol; 2007; 14(1):e2-4. PubMed ID: 17213506
[No Abstract] [Full Text] [Related]
7. Adolescent pharmacology: a pertinent issue of medicine as opposed to medicines.
Kearns GL; Spaulding-Barclay M
Clin Pharmacol Ther; 2008 Dec; 84(6):639-44. PubMed ID: 19008899
[No Abstract] [Full Text] [Related]
8. The way women perceive teratogenic risk.
Koren G
Can J Clin Pharmacol; 2007; 14(1):e10-6. PubMed ID: 17213504
[No Abstract] [Full Text] [Related]
9. Adverse drug reactions in utero: perspectives on teratogens and strategies for the future.
Mitchell AA
Clin Pharmacol Ther; 2011 Jun; 89(6):781-3. PubMed ID: 21593753
[TBL] [Abstract][Full Text] [Related]
10. Drugs used in pregnancy: the regulatory process.
Tomalin A
Can J Clin Pharmacol; 2007; 14(1):e5-9. PubMed ID: 17213510
[No Abstract] [Full Text] [Related]
11. Pharmacodynamic principles in chemical teratology: dose-effect relationships.
Jusko WJ
J Pharmacol Exp Ther; 1972 Dec; 183(3):469-80. PubMed ID: 4636387
[No Abstract] [Full Text] [Related]
12. [Drugs in pregnancy and lactation].
Lauritzen C
Zentralbl Gynakol; 1986; 108(3):137-54. PubMed ID: 3962526
[TBL] [Abstract][Full Text] [Related]
13. Risk minimization practices for pregnancy prevention: understanding risk, selecting tools.
Uhl K; Trontell A; Kennedy D
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):337-48. PubMed ID: 16953517
[TBL] [Abstract][Full Text] [Related]
14. Adolescents in clinical trials.
Kapogiannis BG; Mattison DR
Clin Pharmacol Ther; 2008 Dec; 84(6):655-9. PubMed ID: 19008903
[TBL] [Abstract][Full Text] [Related]
15. [Which drugs are allowed, which should one avoid, which are contraindicated?].
Stahlmann R; Neubert D
Gynakologe; 1987 Jun; 20(2):129-36. PubMed ID: 2887491
[No Abstract] [Full Text] [Related]
16. Risk of drug-induced congenital defects.
De Santis M; Straface G; Carducci B; Cavaliere AF; De Santis L; Lucchese A; Merola AM; Caruso A
Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):10-9. PubMed ID: 15474237
[TBL] [Abstract][Full Text] [Related]
17. Drugs in pregnancy.
Forsell P
Aust Fam Physician; 1982 Dec; 11(12):975-6. PubMed ID: 7159290
[No Abstract] [Full Text] [Related]
18. Adolescent pharmacology.
Tiwari M
Indian Pediatr; 2003 Nov; 40(11):1111-2. PubMed ID: 14660857
[No Abstract] [Full Text] [Related]
19. Cases of babies in Brazil born with thalidomide defects.
Kouros N
Monash Bioeth Rev; 2013 Sep; 31(2):29-30. PubMed ID: 24844079
[No Abstract] [Full Text] [Related]
20. [Drugs and pregnancy].
Lippert TH
Internist (Berl); 1988 Sep; 29(9):630-5. PubMed ID: 3053522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
